- United States
- /
- Medical Equipment
- /
- NYSE:AORT
Artivion, Inc.'s (NYSE:AORT) CEO Looks Like They Deserve Their Pay Packet
Key Insights
- Artivion to hold its Annual General Meeting on 13th of May
- CEO Pat Mackin's total compensation includes salary of US$806.9k
- The overall pay is comparable to the industry average
- Artivion's total shareholder return over the past three years was 44% while its EPS grew by 23% over the past three years
The performance at Artivion, Inc. (NYSE:AORT) has been quite strong recently and CEO Pat Mackin has played a role in it. The pleasing results would be something shareholders would keep in mind at the upcoming AGM on 13th of May. It is likely that the focus will be on company strategy going forward as shareholders hear from the board and cast their votes on resolutions such as executive remuneration and other matters. We think the CEO has done a pretty decent job and we discuss why the CEO compensation is appropriate.
View our latest analysis for Artivion
How Does Total Compensation For Pat Mackin Compare With Other Companies In The Industry?
According to our data, Artivion, Inc. has a market capitalization of US$996m, and paid its CEO total annual compensation worth US$5.5m over the year to December 2024. That's a notable increase of 74% on last year. While we always look at total compensation first, our analysis shows that the salary component is less, at US$807k.
In comparison with other companies in the American Medical Equipment industry with market capitalizations ranging from US$400m to US$1.6b, the reported median CEO total compensation was US$5.3m. From this we gather that Pat Mackin is paid around the median for CEOs in the industry. Furthermore, Pat Mackin directly owns US$18m worth of shares in the company, implying that they are deeply invested in the company's success.
Component | 2024 | 2023 | Proportion (2024) |
Salary | US$807k | US$776k | 15% |
Other | US$4.7m | US$2.4m | 85% |
Total Compensation | US$5.5m | US$3.2m | 100% |
Speaking on an industry level, nearly 25% of total compensation represents salary, while the remainder of 75% is other remuneration. In Artivion's case, non-salary compensation represents a greater slice of total remuneration, in comparison to the broader industry. If total compensation is slanted towards non-salary benefits, it indicates that CEO pay is linked to company performance.
A Look at Artivion, Inc.'s Growth Numbers
Artivion, Inc. has seen its earnings per share (EPS) increase by 23% a year over the past three years. Its revenue is up 9.8% over the last year.
This demonstrates that the company has been improving recently and is good news for the shareholders. It's good to see a bit of revenue growth, as this suggests the business is able to grow sustainably. Moving away from current form for a second, it could be important to check this free visual depiction of what analysts expect for the future.
Has Artivion, Inc. Been A Good Investment?
Most shareholders would probably be pleased with Artivion, Inc. for providing a total return of 44% over three years. This strong performance might mean some shareholders don't mind if the CEO were to be paid more than is normal for a company of its size.
In Summary...
Some shareholders will probably be more lenient on CEO compensation in the upcoming AGM given the pleasing performance of the company recently. Seeing that earnings growth and share price performance seems to be on the right path, the more pressing focus for shareholders at the AGM may be how the board and management plans to turn the company into a sustainably profitable one.
While it is important to pay attention to CEO remuneration, investors should also consider other elements of the business. That's why we did some digging and identified 1 warning sign for Artivion that investors should think about before committing capital to this stock.
Of course, you might find a fantastic investment by looking at a different set of stocks. So take a peek at this free list of interesting companies.
If you're looking to trade Artivion, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentNew: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NYSE:AORT
Artivion
Manufactures, processes, and distributes medical devices and implantable human tissues worldwide.
Reasonable growth potential and fair value.
Similar Companies
Market Insights
Community Narratives
